ASSOCIATION BETWEEN ANXIETY AND DEPRESSION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Open Access
- 1 January 2024
- journal article
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 61, e23128
Abstract
Background: This study aimed to assess the frequency and intensity of anxious and depressive symptoms in patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: This is a descriptive and cross-sectional study, resulting from 106 patients from the Hepatology outpatient clinic at the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP), São Paulo, Brazil without a history of alcohol abuse, verified by the alcohol use disorders identification test (AUDIT). These were assessed using the sociodemographic data sheet, Hospital Anxiety and Depression Scale (HADS), Hamilton Anxiety Rating Scale (HAM-A), and Hamilton Depression Scale (HAM-D). Results: A total of 69.8% were women and 30.2% were men, with a mean age of 61 years. The majority (71.7%) discovered MASLD through routine exams, presenting as comorbidities: Type 2 diabetes mellitus (59.4%), Dyslipidemia (49.1%), Arterial hypertension (68.9%), Obesity (61.3%) and Metabolic syndrome [MetS (63.2%)]. The HADS scale indicates 34% probability of anxiety and 33% depressive symptoms. The Hamilton’s scales of intensity indicates 63.9% severe anxiety and 54.3% severe depression. There is also a relationship between anxiety, depression and the female gender, as well as between depression and MetS. Conclusion: The findings point to the presence of anxiety and depression in more than one third of MASLD patients, most with severe symptoms. The group is concentrated in the elderly, with many comorbidities, including MetS. There was a positive correlation between anxiety, depression and being female; also, being significant between MetS and depression.Keywords
This publication has 60 references indexed in Scilit:
- Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver diseaseAnnals of Hepatology, 2020
- Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low‐Density Lipoprotein CholesterolHepatology Communications, 2019
- Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research GapsHepatology, 2019
- Diet and physical activity in the association between depression and metabolic syndrome: Constances studyJournal of Affective Disorders, 2019
- Depression and metabolic syndrome in the older population: A review of evidenceJournal of Affective Disorders, 2018
- Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and OutcomesClinical Gastroenterology and Hepatology, 2015
- Nonalcoholic Fatty Liver Disease in Morbidly Obese Subjects: Correlation Among Histopathologic Findings, Biochemical Features, and Ultrasound EvaluationObesity Surgery, 2014
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationHepatology, 2012
- Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitisHepatology, 1999
- The Structure of the Genetic and Environmental Risk Factors for Six Major Psychiatric Disorders in WomenArchives of General Psychiatry, 1995